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Abstract: The efficacy of cisplatin-based chemotherapy in ovarian cancer is often limited by the
development of drug resistance. In most ovarian cancer cells, cisplatin activates extracellular
signal-regulated kinase1/2 (ERK1/2) signalling. Phosphoprotein enriched in astrocytes (PEA-15) is
a ubiquitously expressed protein, capable of sequestering ERK1/2 in the cytoplasm and inhibiting
cell proliferation. This and other functions of PEA-15 are regulated by its phosphorylation status.
In this study, the relevance of PEA-15 phosphorylation state for cisplatin sensitivity of ovarian
carcinoma cells was examined. The results of MTT-assays indicated that overexpression of PEA-15AA
(a non-phosphorylatable variant) sensitised SKOV-3 cells to cisplatin. Phosphomimetic PEA-15DD
did not affect cell sensitivity to the drug. While PEA-15DD facilitates nuclear translocation of
activated ERK1/2, PEA-15AA acts to sequester the kinase in the cytoplasm as shown by Western blot.
Microarray data indicated deregulation of thirteen genes in PEA-15AA-transfected cells compared to
non-transfected or PEA-15DD-transfected variants. Data derived from The Cancer Genome Atlas
(TCGA) showed that the expression of seven of these genes including EGR1 (early growth response
protein 1) and FLNA (filamin A) significantly correlated with the therapy outcome in cisplatin-treated
cancer patients. Further analysis indicated the relevance of nuclear factor erythroid 2-related factor
2/antioxidant response element (Nrf2/ARE) signalling for the favourable effect of PEA-15AA on
cisplatin sensitivity. The results warrant further evaluation of the PEA-15 phosphorylation status as
a potential candidate biomarker of response to cisplatin-based chemotherapy.
Keywords: PEA-15; ovarian cancer; cisplatin sensitivity
1. Introduction
Platinum-based drugs have been used to treat ovarian cancer since the late 1970s and cisplatin,
followed by carboplatin-based combinations, has been the standard of care for over 15 years.
As most patients relapse and ultimately succumb to ovarian cancer, new strategies are urgently
required to improve survival. Cisplatin is believed to exert its cytotoxic effects via its interaction
with DNA and formation of DNA adducts, primarily intrastrand crosslinks. This initiates signal
transduction pathways involving among others Ataxia Telangiectasia Mutated (ATM) protein, p53,
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p73 and mitogen-activated protein kinases (MAPK), eventually resulting in cancer cell apoptosis [1].
However, DNA damage-mediated apoptotic signals can be diminished leading to the development of
resistance, which represents a major restraint of cisplatin-based chemotherapy [2].
Among the constituents of DNA damage signalling, mitogen-activated protein kinases (MAPKs)
are of particular interest for their diverse functions in modulating cell death machineries. MAPKs are
a family of structurally-related serine/threonine protein kinases that coordinate various extracellular
stimuli to regulate cell growth and survival [3–5]. There are three major subfamilies of MAPKs:
extracellular signal-regulated kinase (ERK1/2), stress-activated protein kinase (SAPK)/c-Jun N-terminal
kinase (JNK) and p38 MAPK [2].
ERK1 and ERK2 are homologous isoforms that share the same substrate specificity in vitro [6].
These 44- and 42-kDa proteins that phosphorylate a multitude of protein substrates [7,8] share 85%
of amino acid identity. In resting conditions, ERK1/2 is anchored in the cytoplasm by its association
with MEK1/2 [9], the microtubule network [10] or with phosphatases, which contain a nuclear export
signal (NES) [11]. Upon stimulation, ERK1/2 becomes phosphorylated at threonine and tyrosine
residues resulting in its separation from MEK1/2. Then ERK1/2 translocates into the nucleus by passive
diffusion of the monomer [12], active transport of the dimer [13] or by a direct interaction of ERK1/2
with the nuclear pore complex [14]. Upon translocation, activated ERK1/2 phosphorylates the ternary
complex factors Elk-1, Sap-1a and TIF-IA (growth dependent transcription initiation factor) [15–17].
Phosphorylation of Elk-1 enhances transcription of growth-related proteins, such as c-Fos [18].
Phosphoprotein enriched in astrocytes -15 kDa (PEA-15) is a small scaffold protein, ubiquitously
expressed and highly conserved among mammals [19–21]. It is involved in the regulation of several
cellular functions, including glucose metabolism, cell proliferation, apoptosis and survival [22].
Its expression has been shown to be elevated in tumours, including human glioma and mammary
carcinomas [23,24], and in cell lines derived from human larynx, cervix and skin tumours
mboxciteB24-cells-715682,B25-cells-715682. PEA-15 may function as a tumour promoter or suppressor,
regulating both proliferation and apoptosis [26].
PEA-15 has two phosphorylation sites at Ser104 and Ser116 and is preferentially phosphorylated
by protein kinase C (PKC) at Ser104 and by calcium/calmodulin-dependent protein kinase II (CaMKII)
or Akt at Ser116 [20,27,28]. PEA-15 can bind both ERK1/2 and phosphorylated ERK1/2 (p-ERK1/2)
with equal affinity [29]. PEA-15 phosphorylation releases ERK1/2 resulting in its translocation to the
nucleus and activation of the nuclear transcription factor Elk-1 as well as other transcription factors
promoting cell proliferation. As PEA-15 has a nuclear export sequence, it is almost exclusively confined
to the cytoplasm [30]. PEA-15-mediated cytoplasmic sequestration of ERK1/2 was reported to suppress
tumourigenicity in ovarian cancer by diminishing the activity of Elk-1 [31]. Another study found
that PEA-15 expression inhibited cell proliferation by autophagy involving ERK1/2 activation [32].
The functions of PEA-15 are tightly regulated by its phosphorylation status [22]. The impact of
PEA-15 phosphorylation was investigated by Lee et al. [33] in ovarian cancer tissue samples revealing
that tissues from high-grade ovarian tumour were significantly more likely than adjacent normal
tissues to express PEA-15 phosphorylated at both sites. The authors used phosphomimetic and
non-phosphorylatable PEA-15 mutants where the two serine residues of PEA-15 at 104 and 116 positions
were either replaced by two aspartic acid (PEA-15DD) or two alanine (PEA-15AA) residues, respectively.
The non-phosphorylatable PEA-15AA exerted a more pronounced antitumourigenic effect in ovarian
cancer than did the phosphomimetic PEA-15DD [33]. To study the role of PEA-15 phosphorylation in
paclitaxel sensitivity in ovarian cancer, PEA-15AA and PEA-15DD were overexpressed in SKOV-3.ip1,
OVTOKO and HEY cells. All three cell lines showed enhanced sensitivity to paclitaxel when
phosphomimetic PEA-15DD was overexpressed, while nonphosphorylatable PEA-15AA augmented
resistance to paclitaxel [34].
The aim of this work was to investigate the influence of PEA-15 and its phosphorylation status on
cisplatin sensitivity in ovarian carcinoma cells. We show that the non-phosphorylatable PEA-15AA
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sensitises ovarian cancer cells to cisplatin. The results warrant further evaluation of the phosphorylation
state of PEA-15 in order to consider it as a potential biomarker of tumour sensitivity to cisplatin.
2. Materials and Methods
2.1. Chemicals
3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) was purchased from
AppliChem (Darmstadt, Germany), dimethylsulfoxide (DMSO) was ordered from Riedel-de Haën,
(Seelze, Germany), bovine serum albumin (BSA), all-trans-retinoic acid and cisplatin were obtained from
Sigma-Aldrich (Steinheim, Germany), foetal calf serum, penicillin-streptomycin solution, IMDMTM
Medium, trypsin-EDTA solution were ordered from PANTM Biotech (Aidenbach, Germany) and
ultrapure water was obtained using a Purelab Plus TM system from ELGA Labwater (Celle, Germany).
2.2. Cell Lines and Cell Culture
The SKOV-3 ovarian carcinoma cell line (ATCC® HTB77TM) was from American Type Culture
Collection (ATCC). The cisplatin-resistant ovarian carcinoma cell line EFO27rCDDP2000 was derived
from the Resistant Cancer Cell Line (RCCL) collection (www.kent.ac.uk/stms/cmp/RCCL/RCCLabout.
html). Cell backups were frozen with 10% DMSO. Cells were grown as monolayers in IMDMTM
medium supplemented with 10% foetal calf serum, 100 IU/mL penicillin, 0.1 mg/mL streptomycin in
a humidified atmosphere containing 5% CO2. The medium of EFO27rCDDP2000 cells was supplemented
with 2 µg/mL cisplatin. Every ten passages a new backup of cells was thawed in order to avoid
alterations in cell features during cultivation.
2.3. Plasmid Transfection
Cells were transfected with plasmids of interest using K2® transfection system
(Biontex Laboratories GmbH, Munich, Germany) according to the manufacturer’s instruction.
Plasmids used in this study include three DNA constructs of pcDNA3-HAR36 containing two
mutated PEA-15 protein versions and the empty vector. These plasmids were kindly provided by
Prof. Naoto T. Ueno (Breast Medical Oncology, MD Anderson Cancer Center, University of Texas,
Houston, TX, USA). The constructs were originally made by Ramos et al. [21]. The two mutated
versions of PEA-15 protein were PEA-15AA, in which two serine residues at 104 and 116 positions
were replaced with two alanine (A) residues, and PEA-15DD, in which the same serine residues were
replaced with aspartic acid (D). Cells were used for protein expression and chemosensitivity analysis
48 h after transfection.
2.4. Cell Fractionation
Nuclear/cytosol fractionation kit (Biovision Inc., Milpitas, CA, USA) was used for separating the
cytosolic and the nuclear fractions of the transfected cells according to the manufacturer’s protocol.
All steps of the fractionation were performed on ice. To analyse the efficiency of the fractionation,
Western blot analysis was performed for each fraction (nuclear or cytosolic) as described below.
As a marker for the cytosolic fraction, GAPDH was used. For the nuclear fraction, Lamin B1 was used
as an indicator of the purity of the nuclear fraction. No cross-contamination was assumed when the
indicator was detected only in the expected fraction.
2.5. Western Blot
Cells were fractionated as mentioned above or lysed in lysis buffer (50 mM Tris-HCl, 150 mM NaCl,
0.1% SDS, 1 mM NaF, 2 mM Na3VO4, 70% NP-40, 0.5% sodium deoxycholate, 6.24 mM benzamidine
and 0.5 mM PMSF, all from Sigma-Aldrich, Steinheim, Germany) for 30 min on ice. Then the cells were
sonicated on ice using a sonicator with the settings: 60% power, 5 s pulse, 30 s interval, 3 pulses per
sample. The suspensions were centrifuged for 5 min at 18,620× g at 4 ◦C, and the protein content in
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the supernatants was measured using the bicinchoninic acid assay (BCATM Protein Assay Kit, Pierce,
Rockford, IL, USA) [35]. Samples containing 30 µg total protein were subjected to electrophoresis in 12%
SDS-polyacrylamide gel and transferred to a PVDF membrane (Carl Roth GmbH, Karlsruhe, Germany).
The membranes were blocked in 5% milk powder in TBS-T (0.2% Tween-20) for 1 h, rinsed three times
with TBS-T and incubated at 4 ◦C overnight with primary antibodies diluted in TBS-T with 5% BSA.
After washing three times with TBS-T, incubation with the secondary antibody diluted 1:1000 in TBS-T
with 5% milk powder for 1.5 h followed. The monoclonal mouse antibody against UGT1A (diluted
1:1000) sc-271268, the polyclonal rabbit antibody against Nrf2 (diluted 1:500) sc-722 were from Santa
Cruz Biotechnology, Heidelberg, Germany, the monoclonal mouse antibody against HA MMS-101-P
(diluted 1:500) was received from Covance Inc., PA, USA. The secondary HRP-conjugated goat
anti-rabbit (diluted 1:1000) SBA-4030-05 was obtained from Biozol Diagnostica Vertrieb GmbH, Eching,
Germany, the rabbit polyclonal antibody against p-ERK1/2 (Thr202/Tyr204) 9101 (diluted 1:1000) was
ordered from Cell Signaling Technology Europe B.V., Frankfurt (Main), Germany, and the Peroxidase
AffiniPure goat anti-mouse (diluted 1:5000) 115-035-003 was from Jackson ImmunoResearch Europe
Ltd., Cambridgeshire, UK. The detection was performed using a Molecular Imager ChemiDocTM
XRS+ System from Bio-Rad Laboratories GmbH, Munich, Germany. After subsequent triple washing
with TBS-T, the membranes were incubated for 30 min. with the rabbit antibody against GAPDH
(GTX100118, Biozol Diagnostica Vertrieb GmbH, Eching, Germany) diluted 1:20000 or for 1 h with
the rabbit polyclonal antibody to Lamin B1 (GTX-103292, Biozol Diagnostica Vertrieb GmbH, Eching,
Germany) diluted 1:1000 in TBS-T with 5% BSA. After rinsing with TBS-T, the incubation with the
secondary antibody and detection were performed as described above. Densitometric analysis was
performed using ImageLabTM 5.1 software (Bio-Rad Laboratories, Hercules, CA, USA).
2.6. MTT Assay
Cell sensitivity to cisplatin, retinoic acid or their combination was assessed using an MTT-based
assay [36]. In brief, cells were seeded in 96-well microtiter plates (1 × 104 cells/well) and allowed
to attach overnight. Then medium was removed and nine subsequent dilutions of retinoic acid or
cisplatin in medium were added to the cells in triplicate (100 µL/well). For the combination treatment,
cisplatin dilutions each contained 20 µM retinoic acid. After 47 h of incubation, 20 µL of a 5 mg/mL
MTT solution in phosphate buffered saline (PBS) was added to each well, and the cells were incubated
at 37 ◦C for 1 h. The supernatant was discarded, and the formazan crystals formed were dissolved
in 100 µL DMSO. Absorbance of the dye was measured at 570 nm with background subtraction at
690 nm using a Multiskan Ascent® microtiter plate reader (Thermo Fisher Scientific, Langenselbold,
Germany). The results were analysed and the pEC50 values (pEC50 = -log EC50, EC50 = half maximal
effective concentration) were estimated for each independent experiment with the GraphPad PrismTM
6 analysis software package (GraphPad Software, San Diego, CA, USA) using non-linear regression
(sigmoidal dose response, variable slope). The mean pEC50 values were calculated from the results of
several independent experiments and used for the determination of the respective EC50 values.
2.7. cDNA Microarray Analysis
SKOV-3 cells were transfected with PEA-15-HA- (empty vector, EV), PEA-15AA- or
PEA-15DD-containing plasmids, respectively, as described above. Twenty-four hours after transfection,
cells were treated with 15 µM cisplatin (this concentration corresponds to the EC50 of cisplatin in
EV-transfected cells as measured after 48 h of incubation) for 24 h and then the total RNA of the cells
was extracted using my-Budget RNA mini kit following the instructions provided by the manufacturer.
Next generation transcriptome-wide gene-level expression profiling using ClariomTM S assay was
performed by Life and Brain GmbH (Bonn, Germany). The microarray data have been deposited into
the Gene Expression Omnibus database under the accession number GSE144041.
The raw data of the array were collected as CEL files and analysed using the Transcriptome
Analysis Console (TAC 4.1, Thermofisher Scientific, Waltham, MA, USA) software. The gene expression
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was analysed with the Gene Level Signal Space Transformation-Robust Multi-Chip Analysis (SST-RMA)
summarization method. Data obtained from the microarray were normalised by the robust multiarray
average method [37]. a probe set was considered expressed if ≥50% samples had DABG (Detected
Above Background) values below DABG threshold (p < 0.05). Statistical significance of the differences
in gene expression was analysed using Limma [38]. Differential expression was assumed at a p value
<0.05 and a fold change in expression ≥2 or ≤−2.
2.8. Correlation of Tumour Gene Expression Levels with the Survival of Cisplatin-Treated Patients in The
Cancer Genome Atlas (TCGA)
Gene expression data from patient tumours was derived from The Cancer Genome
Atlas (TCGA) [39,40] via the GDC Data Portal (https://portal.gdc.cancer.gov). The Bioconductor
R package TCGAbiolinks was used to obtain corresponding clinical data. Tumour gene expression
data and cisplatin response data were available for 779 patients representing 23 different cancer types
(adrenocortical carcinoma, n = 2; bladder urothelial carcinoma, n = 78; breast invasive carcinoma, n = 2;
cervical squamous cell carcinoma and endocervical adenocarcinoma, n = 122; cholangiocarcinoma,
n = 4; lymphoid neoplasm diffuse large b-cell lymphoma, n = 2; oesophageal carcinoma, n = 14;
glioblastoma multiforme, n = 7; head and neck squamous cell carcinoma, n = 94; kidney renal papillary
cell carcinoma, n= 1; liver hepatocellular carcinoma, n= 4; lung adenocarcinoma, n= 84; lung squamous
cell carcinoma, n = 72; mesothelioma, n = 34; ovarian serous cystadenocarcinoma, n = 115; pancreatic
adenocarcinoma, n = 2; sarcoma, n = 3; skin cutaneous melanoma, n = 9; stomach adenocarcinoma,
n = 44; testicular germ cell tumours, n = 53; thymoma, n = 5; uterine corpus endometrial carcinoma,
n = 21; uterine carcinosarcoma, n = 7). Overall survival (OS) was defined as days to last follow-up or
death as previously described [41].
Genes whose expression was undetected (FPKM = 0, FPKM – fragments per kilobase of
exon model per million reads mapped) in >10% samples were removed from the investigation
as previously described [42]. Patients were stratified by cancer type, and the median expression for
each gene was calculated. Genes with expression values above the median were considered highly
expressed, while those below the median were considered to have low expression. Patients were then
re-amalgamated before being stratified by drug treatment for pan-cancer analysis.
Cox proportional hazards regression was used to calculate the hazard ratio for cohorts expressing
high (above-median) vs. low (below-median) levels of a given gene. Calculations were performed
using the R survminer and survival packages. p-values in each case are the result of a log rank
(Mantel-Cox) test, which assesses whether there is a significant difference between the survival of
two independent groups. Hazard ratios quoted refer to values for ‘low’ (below median) expression
for each gene in the model, with values >1 indicating increased hazard (i.e., reduced OS) and values
<1 indicating decreased hazard (i.e., increased OS). Multiple test correction was again performed for
each of the samples (Benjamini-Hochberg method [43]). The false discovery rate (FDR) values are
thresholds that indicate whether p-values are below or above the respective significance levels.
2.9. Statistical Analysis
GraphPad PrismTM 6 was used for analysing and plotting the data. Protein expression data were
compared using one-way ANOVA with a Holm-Sidak post-test. Unpaired t-test was used to compare
pEC50 values. p values of <0.05 were considered significant.
3. Results
3.1. PEA-15AA Sensitised SKOV-3 Cells to Cisplatin
In order to assess if the phosphorylation status of PEA-15 affects cisplatin sensitivity,
the non-phosphorylatable PEA-15AA (further AA) and the phosphomimetic PEA-15DD (further DD)
were overexpressed in SKOV-3 cells by liposome-mediated transient transfection. Control cells were
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transfected with the empty vector (further EV). The efficiency of the transfection was confirmed by
Western blot (Figure 1a). PEA-15AA overexpression significantly increased the sensitivity of SKOV-3
cells to cisplatin compared to the empty vector-transfected cells (Figure 1b). This was not the case
upon PEA-15DD overexpression. The EC50 in SKOV-3-AA cells was lower (EC50 = 9.9 µM) than
in SKOV-3-EV cells (14.9 µM), while SKOV-3-DD cells (EC50 = 14.3 µM) showed similar cisplatin
sensitivity as the SKOV-3-EV controls.
Figure 1. (a) Expression of hemagglutinin (HA)-tagged phosphoprotein enriched in astrocytes (PEA-15)
in SKOV-3 cells after transfection with the HA-tagged empty vector (EV), PEA-15AA (AA) and
PEA-15DD (DD). GAPDH was used as a loading control. (b) Cisplatin sensitivity (pEC50, mean ± SEM,
n = 8) of transfected SKOV-3-EV (EV), SKOV-3-AA (AA) and SKOV-3-DD (DD) cells. *** p < 0.001,
n.s. = not significant.
In addition, we confirmed the effect of PEA-15AA on cisplatin sensitivity in the cisplatin-resistant
EFO27rCDDP2000 ovarian carcinoma cell line. Non-phosphorylatable PEA-15 significantly sensitised
EFO27rCDDP2000 cells to the platinum drug (Figure S1). The EC50 value after PEA-15AA transfection
was 25.1 µM and thus lower than that of 33.1 µM in cells transfected with the empty vector.
Overexpression of PEA-15DD did not have any significant effect (EC50 = 30.9 µM) compared to
the empty-vector control.
3.2. PEA-15AA-Transfected SKOV-3 Cells Contain more Cytosolic p-ERK1/2 than PEA-15DD-Transfected Cells
EV-, PEA-15AA- and PEA-15DD-transfected SKOV-3 cells were fractionated to separate the
nuclear and cytosolic fractions. Figure 2 presents relative expression of activated ERK in the cytosolic
and nuclear fractions of the same samples following transfection with different mutants of PEA-15,
loaded on the same gel. In SKOV-3-AA cells, the cytosolic fraction contained more p-ERK1/2 than the
corresponding nuclear fraction of the same cell lysate, while in SKOV-3-DD cells the opposite was
observed (Figure 2). This provides a proof of concept that PEA-15 unphosphorylated at both Ser104 and
Ser116 (PEA-15AA) retains p-ERK1/2 in the cytoplasm of SKOV-3-AA cells while the phosphomimetic
PEA-15DD does not keep p-ERK1/2 in the cytoplasm, promoting an increase in p-ERK1/2 nuclear
accumulation in SKOV-3-DD cells.
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Figure 2. A representative Western blot of phosphorylated extracellular signal-regulated kinase1/2
(p-ERK1/2) expression in nuclear and cytosolic fractions of the SKOV-3 cells transfected with empty
vector (EV), PEA-15AA (AA) and PEA-15DD (DD). GAPDH and Lamin B1 were used as the markers
and loading controls of cytosolic (C) and nuclear fractions (N), respectively.
3.3. Differentially Expressed Genes in Transfected Cells
As PEA-15 has many other functions inside the cells beside controlling ERK1/2 localisation,
a microarray analysis was warranted to identify genes, which may account for enhanced cisplatin
sensitivity in PEA-15AA-transfected cells. ClariomTM S assay was performed to analyse the differences
in gene expression in untreated and cisplatin-treated SKOV-3-EV, SKOV-3-AA and SKOV-3-DD cells.
Genes were considered to be differentially expressed when the fold change was ≥2 and the p value
was <0.05. The resulting heat map of regulated genes shows clear clustering between treatment
conditions (Figure 3).
Figure 3. Heatmap of the transcriptome-wide ClariomTM S array, regulated genes with fold change
cut-off at 2.0 for differentially expressed genes and a p-value cut-off at 0.05 are shown.
Table 1 shows the number of differentially expressed genes in EV-, PEA-15AA- and
PEA-15DD-transfected cells after cisplatin exposure and in untreated transfected cells. Prior to
cisplatin exposure, only three genes were differentially regulated between untreated SKOV-3-EV and
untreated SKOV-3-AA. Between SKOV-3-EV and SKOV-3-DD, the number of differentially expressed
genes was 18, while for SKOV-3-AA and SKOV-3-DD the number was 10. Following cisplatin
treatment, 4430 genes were differentially regulated in EV-transfected cells, while in PEA-15AA- and
PEA-15DD-transfected cells the numbers were 4196 and 4110, respectively.
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Table 1. Number of differentially expressed genes, compared as treatment condition 1 vs. condition 2
with at least two-fold up- or down-regulation with p < 0.05.
Treatment Condition 1 Treatment Condition 2 Number of Genes
SKOV-3-EV, untreated SKOV-3- AA, untreated 3
SKOV-3-EV, untreated SKOV-3-DD, untreated 18
SKOV-3-AA, untreated SKOV-3- DD, untreated 10
SKOV-3-EV, untreated SKOV-3-EV, 15 µM cisplatin, 24 h 4430
SKOV-3-AA, untreated SKOV-3-AA, 15 µM cisplatin, 24 h 4197
SKOV-3-DD, untreated SKOV-3-DD, 15 µM cisplatin, 24 h 4110
3.4. Correlation of Genes Differentially Expressed in the Comparisons Untreated SKOV-3-AA vs. SKOV-3-EV
and SKOV-3-AA vs. SKOV-3-DD Cells with the Survival of Cisplatin-Treated Patients in The Cancer Genome
Atlas (TCGA)
Next, we selected genes, which were differentially regulated in comparisons: SKOV-3-AA vs.
SKOV-3-EV and SKOV-3-AA vs. SKOV-3-DD. Then we checked the expression levels of those 13 genes
in the tumours of cisplatin-treated cancer patients and correlated them to patient survival (Table 2).
Table 2. Correlation of the expression of genes, differentially expressed between SKOV-3-AA and
SKOV-3-EV or SKOV-3-DD cells, in tumours of cisplatin-treated patients (n = 779) and patient survival.
Gene Fold Change Hazard Ratio 1 p-Value FDR (thr. 0.2) 2 FDR (thr. 0.05)
EGR1 −2.22 0.7068 0.00322 ** 0.034099 0.008525
NAV3 −2.18 0.7062 0.00317 ** 0.033948 0.008487
GPRC5C 2.14 1.4745 0.000971 ** 0.023936 0.005984
Gene Fold change Hazard ratio 1 p-value FDR (thr. 0.2) 2 FDR (thr. 0.05)
TSTD3 2.16 0.7545 0.0162 * 0.053933 0.013483
ELFN2 2.09 0.9036 0.385 0.139261 0.034815
LOC100287225 −2.37 n.a. 3 n.a. n.a. n.a.
TIPARP −2.19 0.7505 0.015 * 0.052694 0.013174
PRKG1 −2.00 0.7532 0.0154 * 0.053205 0.013301
ND6 −2.07 0.8492 0.163 0.10641 0.026602
RBM26 −2.42 0.8951 0.342 0.133674 0.033418
FLNA −2.86 0.7523 0.0152 * 0.052997 0.013249
MAVS −2.24 0.6656 0.000569 ** 0.020231 0.005058
GTSF1L −2.07 n.a. n.a. n.a. n.a.
1 Hazard ratio at low gene expression levels in tumour tissue; 2 thr. = false discovery rate threshold determined
according to Benjamini-Hochberg [43]; 3 n.a. = not applicable; * = p-value below 0.05 and significant at FDR = 0.2;
** = p-value below 0.05 and significant at FDR = 0.05.
Patient survival is expressed as the hazard ratio at low (below median) expression of the respective
gene in tumour tissue. a hazard ratio >1 means that the overall survival is reduced in patients with
tumours that display low expression of the respective gene. a hazard ratio <1 indicates prolonged
survival in patients, whose tumours display low expression of the respective genes. When we
prepared a heatmap, in which we directly compared the effect of low expression of the investigated
genes on cisplatin sensitivity or patient survival, there was substantial overlap as illustrated in
Figure 4. The expression levels of nine of the eleven genes, for which gene expression data was
available in the TCGA, were associated with beneficial (low EC50, prolonged survival) or poor (high
EC50, shorter survival) outcome in the same way in both datasets (Table 2, Figure 4). There was
a significant correlation (at a FDR of 0.2) for seven of these nine genes between their expression level
in tumour tissue and patient survival: early growth response protein 1 (EGR1), neuron navigator 3
(NAV3), G Protein-Coupled Receptor Class C Group 5 Member C (GPRC5C), TCDD-inducible poly
[ADP-ribose] polymerase (TIPARP), cGMP-dependent protein kinase 1 (PRKG1), filamin a (FLNA),
mitochondrial antiviral-signalling protein (MAVS).
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Figure 4. Heatmap indicating the relationship between low expression of the indicated genes and
sensitivity/outcome, favourable (low cisplatin EC50 in SKOV-3-AA cells or prolonged survival of
cisplatin-treated patients, indicated in yellow) or unfavourable (high cisplatin EC50 in SKOV-3-AA
cells or reduced survival of cisplatin-treated patients, indicated in blue), based on the comparison of
gene expression between SKOV-3-AA and EV- or PEA-15DD-transfected variants and TCGA data.
3.5. Pathway Analysis for the Genes Exclusively Regulated in SKOV-3-AA Cells Following Cisplatin Treatment
Since cisplatin treatment had a major impact on gene expression, we created a Venn diagram to
define the genes exclusively regulated upon cisplatin treatment in different transfected cells. For all
three cell types, 3039 differentially regulated genes were common. However, 717 genes were exclusively
regulated after cisplatin exposure in SKOV-3-EV cells, while in SKOV-3-AA and SKOV-3-DD cells 444
genes and 383 genes were exclusively differentially expressed, respectively (Figure 5). The 444 genes
that were found to be exclusively regulated in SKOV-3-AA cells upon cisplatin exposure may contribute
to the increased cisplatin sensitivity in these cells. a pathway analysis based on Wikipathways revealed
21 pathways to be significantly affected in response to cisplatin treatment in SKOV-3-AA cells (Figure 6).
Figure 5. Venn diagram representing the exclusively and commonly regulated genes in different
transfected cells upon cisplatin exposure. The diagram shows the total number of genes affected by
cisplatin exposure in empty vector—(EV), PEA-15AA—(AA) and PEA-15DD-transfected—(DD) cells.
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Figure 6. Twenty-one biological pathways significantly affected by cisplatin treatment in SKOV-3-AA
cells, listed according to the significance level (log 2 base) in a descending order.
The most significantly affected pathway was the glucuronidation pathway with a significance value
of 9.9 (log 2 base). Glucuronidation is the process of metabolizing substances such as drugs, pollutants,
bilirubin, androgens, estrogens, glucocorticoids, fatty acids and bile acids. In glucuronidation process,
the glucuronic acid of a uridine diphosphate (UDP) glucuronic acid is transferred to a substrate by
UDP-glucuronyl transferase (UGT). The resulting substrates, glucuronides are more soluble in water
and are excreted from body with urine and faeces. Among the other significant pathways, the Nrf2
pathway is of importance, as it is an upstream regulator of the UGTs. In addition, this pathway was
previously found to influence cisplatin sensitivity in cancer cells [44].
3.6. Evaluation of the Responsible Genes Within the Affected Pathways
3.6.1. UGT1A and Nrf2 Pathway
All ten UGT1A isoforms were downregulated in SKOV-3-AA cells after cisplatin exposure
according to the microarray data. Western blot analysis indicated that the expression of UGT1A protein
in EV-, PEA-15AA- and PEA-15DD-transfected cells decreased in response to cisplatin to 55.63%
(p = 0.02), 38.65% (p = 0.0013) and 48.27% (p = 0.01) of their basal level in untreated cells, respectively
(Figure 7a). The greatest extent of reduction after cisplatin exposure was thus observed after PEA-15AA
transfection (61.35% in SKOV-3-AA compared to 44.37% for SKOV-3-EV and 51.73% for SKOV-3-DD,
along with much lower p-value).
The UGT1A family is also annotated in other pathways significantly affected by cisplatin
treatment in SKOV-3-AA cells, including codeine and morphine metabolism, estrogen metabolism,
aryl hydrocarbon receptor pathway, irinotecan pathway, nicotine metabolism, tamoxifen metabolism
and Nrf2 pathway. Nrf2 is the upstream regulator of UGT1A expression. The array did not show
any differential regulation of Nrf2, but some downstream genes of Nrf2 were differentially expressed.
Therefore, the expression of Nrf2 was analysed on the protein level by Western blot in transfected
cells before and after exposure to cisplatin (Figure 7b). The results showed a slight decrease in the
overall Nrf2 levels after cisplatin exposure in all investigated cells. However, the differences were not
statistically significant conforming to the result of the array.
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Figure 7. Representative Western blots and the corresponding densitometric quantification
(mean ± SEM, n = 3) of (a) the relative uridine diphosphate-glucuronyl transferase (UGT)1A expression
and (b) the relative nuclear factor erythroid 2-related factor 2 (Nrf2) expression in empty vector—(EV),
PEA-15AA—(AA) and PEA-15DD-transfected—(DD) cells after treatment with 15 µM cisplatin (+Pt)
for 24 h and in untreated transfected SKOV-3 cells. GAPDH was used as a loading control. * p < 0.05,
** p < 0.01.
3.6.2. Retinoic Acid, an Inhibitor of Nrf2/ARE Pathway, Increases Cisplatin Sensitivity
Since UGT1A expression was affected by cisplatin in SKOV-3-AA cells, while Nrf2 expression
was not, we hypothesised that Nrf2-associated downstream signalling via the Nrf2/ARE pathway
may contribute to the sensitisation of PEA-15AA-transfected cells to cisplatin. All-trans retinoic acid
(further retinoic acid), which is known to reduce the Nrf2-mediated induction of ARE-driven genes [45],
was used to investigate this phenomenon further.
The EC50 value of retinoic acid was 216 µM (pEC50 = 3.660 ± 0.003, mean ± SEM, n = 6) after 48 h
of incubation. In order to investigate the influence of the compound on cisplatin sensitivity, 20 µM of
retinoic acid was used in combination with cisplatin in SKOV-3 cells as this concentration was lower
than the EC10 of retinoic acid and therefore not toxic to the cells.
Retinoic acid did not affect Nrf2 protein levels in all investigated cells independent of cisplatin
treatment (Figure 8a). However, retinoic acid significantly reduced UGT1A levels alone and in
combination with cisplatin (Figure 8b). This suggests that retinoic acid interferes with UGT1A
expression via effects on Nrf2 signalling (but without directly affecting Nrf2 levels) similarly to
PEA-15AA overexpression. In agreement, retinoic acid also significantly sensitised SKOV-3 cells
to cisplatin (Figure 9). The EC50 value for cisplatin decreased from 32.6 µM to 13.9 µM in the
presence of 20 µM retinoic acid. It should be noted that this experiment was conducted with
non-transfected SKOV-3 cells, which cannot be directly compared with empty vector-transfected
cells. Generally, after transfection process, cells became more sensitive to cisplatin. a similar effect of
transfection procedure was also noticed in EFO27rCDDP2000 cells (Figure S1).
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Figure 8. Representative Western blots and the corresponding densitometric quantification
(mean ± SEM, n = 3) of (a) the relative Nrf2 expression and (b) the relative UGT1A expression
in the transfected untreated SKOV-3 cells (Ctrl), after exposure to 15 µM cisplatin (Pt), to 20 µM retinoic
acid (RA) and after co-incubation with 20 µM retinoic acid and 15 µM cisplatin (Pt + RA) for 24 h are
shown. GAPDH was used as a loading control. *p < 0.05, ** p < 0.01, n.s. = not significant.
Figure 9. Sensitivity of SKOV-3 cells (pEC50, mean ± SEM, n = 9–10) of cisplatin alone (Pt), and upon
co-incubation with 20 µM retinoic acid (Pt + RA) was determined over 48 h. *** p < 0.001.
4. Discussion
Our results show that overexpression of PEA-15AA, a PEA-15 variant that cannot be
phosphorylated at Ser104 and Ser116, increases the sensitivity of SKOV-3 ovarian cancer cells to
cisplatin. The modest absolute effect of PEA-15 phosphorylation status on pEC50 may result from
counteracting signalling pathways. Nevertheless, the finding was confirmed in an additional cell
line model.
Previously, PEA-15 overexpression was found to induce cisplatin resistance and knockdown of
PEA-15 was shown to enhance sensitivity to cisplatin in colorectal carcinoma cell line [46]. In that case,
the wild-type PEA-15 was overexpressed, with both regulatory serine residues (Ser104 and Ser116)
open to be phosphorylated. Therefore, the observed effects cannot be attributed to a single factor, i.e.,
overexpression of PEA-15. Our results indicate that PEA-15 phosphorylation status critically determines
the cancer cell response to cisplatin. Non-phosphorylatable PEA-15AA had been previously found to
inhibit ovarian cancer tumourigenicity and progression by blocking beta-catenin [33]. However, we did
not observe direct effects of PEA-15AA on cell growth kinetics. PEA-15 phosphorylation at Ser116
rendered glioblastoma cells resistant to glucose-deprivation mediated cell death [47], which is in line
with our finding that unphosphorylatable PEA-15 can potentiate cytotoxic effects. However, it appears
to be not the case for all kinds of toxic stimuli. Interestingly, PEA-15AA had been shown to
reduce ovarian cancer cell sensitivity to paclitaxel [34], a drug that interferes with microtubule
disassembly [48], whereas cisplatin acts in a different fashion directly inducing DNA damage [1].
PEA-15 phosphorylation status affects several signalling pathways and apparently, depending on the
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mode of action, different downstream events gain more importance accounting for the diverging effects
on cell sensitivity to different drugs.
In agreement with previous reports, PEA-15AA retained activated ERK1/2 in the cytoplasm.
However, due to the diverse cellular functions of PEA-15, a microarray analysis was warranted to
investigate the underlying key players of sensitisation of SKOV-3 cells to cisplatin by PEA-15AA.
In untreated cells, PEA-15-AA overexpression resulted in the differential regulation of thirteen
genes between SKOV-3-AA and SKOV-3-EV or SKOV-3-DD cells. For eleven of these genes, data from
cisplatin-treated patients was available in TCGA, and the expression of seven genes significantly
correlated with the outcome of cisplatin therapy in the same way as expected from our data. Some of
these genes are of particular interest in the context of ERK1/2 signalling. Early growth response
protein 1 (EGR1) is a downstream nuclear target of Elk-1, which itself is regulated by activated ERK1/2
upon nuclear translocation [49,50], suggesting that PEA-15AA-mediated retention of activated ERK1/2
in the cytosol results in reduced EGR1 expression. Low EGR1 levels have also been reported to
correlate with high cisplatin sensitivity in primary glioma cells [51]. FLNA, coding for filamin A,
a non-muscle actin filament cross-linking protein, is a downstream target of the nuclear transcription
factor Sp1 [52], which is also regulated by ERK1/2 [53]. Reduced FLNA levels were observed in
PEA-15AA-transfected cells in this study, and also correlated with increased cisplatin sensitivity in
a mouse xenograft model [54] and with improved overall survival in patients [55] according to previous
reports. Filamin a was also found to promote cancer growth [56] and to play an important role in
repair of DNA damage [57].
A total of 444 genes were exclusively differentially regulated in cisplatin-treated SKOV-3-AA
cells with UGT1A family representing the most significantly affected pathway (glucuronidation).
UGTs catalyse the addition of a β-glucuronic acid moiety to a variety of nucleophilic sites of xenobiotics
and endogenous compounds including bilirubin, steroids, bile acids, drugs and other carcinogenic and
toxic compounds [58], and have been linked to drug resistance in cancer. The downregulation of UGT1A
enzymes upon cisplatin exposure is likely to be a consequence of suppression of upstream signalling
via Nrf2 pathway, which was also affected in response to cisplatin treatment. However, effects did not
involve Nrf2 itself but seemed to be rather mediated by downstream signalling events. Retinoic acid,
a known inhibitor of Nrf2/ARE signalling reduced UGT1A levels and increased cisplatin sensitivity of
SKOV-3 cells independently of Nrf2 expression in a similar fashion as PEA-15AA overexpression.
PEA-15 was already evaluated for treating advanced breast cancer in mice. To target PEA-15 in
advanced breast tumours, Xie et al. developed a breast cancer specific construct (T-VISA) composed of
the human telomerase reverse transcriptase (hTERT; T) promoter and a versatile transgene amplification
vector VISA (VP16-GAL4-WPRE integrated systemic amplifier). T-VISA-PEA-15 was found to be
highly specific, to selectively express PEA-15 in breast cancer cells, and to induce cancer cell killing
in vitro and in vivo without affecting normal cells [58]. a similar construct with PEA-15AA would be of
interest for ovarian cancer in order to investigate if the efficacy of cisplatin treatment can be improved.
In conclusion, non-phosphorylatable PEA-15AA increases cisplatin sensitivity of ovarian cancer
cells, suggesting that the phosphorylation status of PEA-15 could be evaluated as a biomarker to
predict the responsiveness of ovarian tumours to cisplatin treatment. For this purpose, correlation of
PEA-15 phosphorylation with therapy outcome in high-grade serous ovarian cancer is needed, as this
subtype is the most aggressive and has the worst prognosis [59].
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with empty vector (EV), with PEA-15AA (AA), and with PEA-15DD (DD). ***p < 0.001, n.s. = not significant.
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